Molecular testing is the only way for early detection of breast cancer. Mutational analysis for a limited set of founder
mutations requires much less time, resources, and labor than complete sequencing. Recommendations can be made for public health action on molecular genetic testing. The increased public awareness of the nature and prevalence of breast cancer may result in an increased demand for genetic testing for breast cancer susceptibility. It is valuable to offer genetic testing to newly diagnosed cases with breast cancer for the purpose of clinical management and as a mean to identify presymptomatic carrier relatives for prevention. Acknowledgements Thanks go to Dr. Elsayed S. Abdel- Razik for his valuable assistance in graphic processing. References 1. Marcus JN, Watson P, CHIR98014 solubility dmso Page DL, Narod SA, Lenoir GM, Tonin P: Adriamycin datasheet Hereditary breast cancer: pathobiology, prognosis, and BRCA1and BRCA2
gene linkage. Cancer 1996, 77:697–709.PubMedCrossRef 2. Omar S, Khaled H, Gaafar R, Zekry AR, Eissa S, El-Khatib O: Breast cancer in Egypt: a review of disease presentation and detection strategies. Eastern Mediterranean Health Journal 2003, 9:448–463.PubMed 3. Parker SL, Tong T, Bolden S, Wingo PA: Cancer statistics. Cancer J Clin 1997, 47:5–27.CrossRef 4. Shattuck-Eidens D, Oliphant A, McCuire M, McBride C, Gupte J: BRCA1 sequence analysis in women at high Trichostatin A nmr risk for susceptibility mutations. Risk factor analysis and implications for genetic testing. JAMA 1997, 278:1242–1250.PubMedCrossRef 5. Rebbeck TR: Inherited
genetic predisposition in breast cancer. A population-based perspective. Cancer 1999,86(Suppl):1673–1681.CrossRef 6. Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavigian S: A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994, 266:66–71.PubMedCrossRef 7. Wooster R, Neuhaussen SL, Mangion J, Quick Y, Ford D, Collin N: Localization of a breast cancer susceptibility gene; BRCA2, to chromosome 13q 12 .i 3 . Science Pembrolizumab molecular weight 1994, 265:2088–2090.PubMedCrossRef 8. Chapman MS, Verma IM: Transcriptional activation by BRCA1. Nature 1996, 382:678–679.PubMedCrossRef 9. Scully R, Chen J, Plug A, Xiao Y, Weaver D, Feunteun J: Association of BRCA1 with RaD51 in mitotic and meiotic cells. Cell 1997, 88:265–275.PubMedCrossRef 10. Tavtigian SV, Simard J, Rommers J, Couch F, Shattuck-Eidens D, Neuhausen S: The complete BRCA2 gene and mutations in chromosome 13q-linked kindreds. Nat Genet 1996, 12:333–337.PubMedCrossRef 11. Chen J, Silver P, Walpita D, Cantor B, Gazdar F, Tomlinson G: Stable interaction between the products of the BRCA1 and BRCA2 tumor suppressor genes in mitotic and meiotic cells. Mol Cell 1998, 2:317–328.PubMedCrossRef 12. Yoshida K, Miki M: Role of BRCA1 and BRCA2 as regulators of DNA repair, transcription, and cell cycle in response to DNA damage. Cancer Sci 2004, 95:866–871.PubMedCrossRef 13.